Parameters	Lower boundary	Upper boundary
PCV-7 cost per dose	US$102.38	US$170.63
Reduction of IPD for herd immunity in children (<5 year)	51.8%	86.3%
Annually incidence of IPD in children (<5 year)	0.0124%	0.0206%
S. pneumoniae isolation rate for pneumonia	2.0%	26.8%
Annually incidence of all-cause AOM (3-5year)	1.2%	64.0%
Utility of disability	0.7	0.5
Probability of disability caused by meningitis in adults	14.3%	23.8%
Cost of AOM per episode	US$31.75	US$317.46
Annually incidence of all-cause AOM (≤2 year)	1.2%	64.0%
Utility of deafness	0.85	0.75
Probability of deafness caused by meningitis in adults	19.5%	32.5%
S. pneumoniae isolation rate for AOM	29.2%	49.0%
Serotype coverage of PCV-7 for AOM	49%	81%
Efficacy of PCV-7 for preventing AOM	43.2%	72.0%
Cost of pneumonia per episode	US$158.73	US$1,587.30
Salary per day	US$6.30	US$27.64
Serotype coverage of PCV-7 for IPD	15%	93%
Vaccine coverage	80%	100%
Workloss for AOM	4 day	8 day
Serotype coverage of PCV-7 for pneumonia	57%	95%
Annually incidence of all-cause pneumonia	9.6%	16.0%
Efficacy of PCV-7 for preventing pneumonia	68%	100%
Annually incidence of IPD in old children (5-18 years)	0.0011%	0.0018%
Reduction of IPD for herd immunity in old children (5-20 ye	22.5%	37.5%
Probability of tympanostomy caused by AOM	4.4%	7.4%
Utility of tympanostomy caused by AOM	0.865	0.775
Cost of vaccine administration	US$0.00	US$3.17
Relative efficacy of PCV7 for 2 doses	64.5%	100.0%
Case-fatality rate of pneumonia	0.39%	0.66%
Reduction of IPD for herd immunity in adults (⩾65 years)	0.0%	31.0%
Relative efficacy of PCV7 for 3 doses	95.0%	100.0%
Efficacy of PCV-7 for preventing IPD	73.1%	100.0%
Utility of AOM	0.99625	0.99375
Proportion of meningitis in IPD	25.0%	41.7%
Probability of disability caused by meningitis in children	5.3%	8.8%
Reduction of IPD for herd immunity in adults (35-64 years)	0.0%	20.0%